212 related articles for article (PubMed ID: 25684345)
1. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
LoRusso PM; Goncalves PH; Casetta L; Carter JA; Litwiler K; Roseberry D; Rush S; Schreiber J; Simmons HM; Ptaszynski M; Sausville EA
Invest New Drugs; 2015 Apr; 33(2):440-9. PubMed ID: 25684345
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K; Karan S; Simmons H; Marcus AI; Ptaszynski M; Kantarjian H
Cancer; 2012 Jul; 118(14):3556-64. PubMed ID: 22139909
[TBL] [Abstract][Full Text] [Related]
3. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
Infante JR; Patnaik A; Verschraegen CF; Olszanski AJ; Shaheen M; Burris HA; Tolcher AW; Papadopoulos KP; Beeram M; Hynes SM; Leohr J; Lin AB; Li LQ; McGlothlin A; Farrington DL; Westin EH; Cohen RB
Cancer Chemother Pharmacol; 2017 Feb; 79(2):315-326. PubMed ID: 28097385
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Shah JJ; Kaufman JL; Zonder JA; Cohen AD; Bensinger WI; Hilder BW; Rush SA; Walker DH; Tunquist BJ; Litwiler KS; Ptaszynski M; Orlowski RZ; Lonial S
Cancer; 2017 Dec; 123(23):4617-4630. PubMed ID: 28817190
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
Wakui H; Yamamoto N; Kitazono S; Mizugaki H; Nakamichi S; Fujiwara Y; Nokihara H; Yamada Y; Suzuki K; Kanda H; Akinaga S; Tamura T
Cancer Chemother Pharmacol; 2014 Jul; 74(1):15-23. PubMed ID: 24752449
[TBL] [Abstract][Full Text] [Related]
6. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
[TBL] [Abstract][Full Text] [Related]
8. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
Holen KD; Belani CP; Wilding G; Ramalingam S; Volkman JL; Ramanathan RK; Vasist LS; Bowen CJ; Hodge JP; Dar MM; Ho PT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):447-54. PubMed ID: 20461380
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A; Htut M; Zonder JA; Fay JW; Jakubowiak AJ; Levy JB; Lau K; Burt SM; Tunquist BJ; Hilder BW; Rush SA; Walker DH; Ptaszynski M; Kaufman JL
Cancer; 2016 Nov; 122(21):3327-3335. PubMed ID: 27433944
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
[TBL] [Abstract][Full Text] [Related]
11. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
12. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
14. Filanesib for the treatment of multiple myeloma.
Algarín EM; Hernández-García S; Garayoa M; Ocio EM
Expert Opin Investig Drugs; 2020 Jan; 29(1):5-14. PubMed ID: 31815551
[No Abstract] [Full Text] [Related]
15. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
17. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
20. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
